Alnylam Files Opposition Against Silence Patent in Europe
November 18, 2010
Alnylam Files Opposition Against Silence Patent in Europe
Notably, the patent in dispute is part of the so-called Zamore IP family. Alnylam's top official earlier this year publicly dismissed a related US patent from the Zamore family as "not worth anything."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
July 28, 2011 / Gene Silencing News - Silence Responds to Alnylam European Patent Claims
March 15, 2012 / Gene Silencing News - Alnylam RNAi IP Upheld in European Opposition Proceedings
December 2, 2010 / Gene Silencing News - Alnylam Execs Downplay Importance of Silence Therapeutics' Zamore IP
August 12, 2010 / Gene Silencing News - USPTO Upholds Silence's 'Zamore Design Rules' Patents
December 15, 2011 / Gene Silencing News